Human Epididymis Protein 4 in Transcatheter Aortic Valve Implantation
Elevated HE4 serum levels are associated with diffuse myocardial fibrosis and increased risk of adverse clinical events following TAVI. This promising blood biomarker may be helpful to enhance risk stratification in patients undergoing TAVI.
Authors
- Sébastien Hecht (ORCID: https://orcid.org/0000-0002-5408-8576)
- Philippe Pîbarot (ORCID: https://orcid.org/0000-0002-3607-279X)
- Robert DeLarochellière
- Julio I. Farjat‐Pasos (ORCID: https://orcid.org/0000-0002-8353-7625)
- Carlos Giuliani (ORCID: https://orcid.org/0000-0002-3157-4598)
- Rami Abu-Alhayja’a
- Jean‐Michel Paradis (ORCID: https://orcid.org/0000-0002-3428-617X)
- Josep Rodés‐Cabau (ORCID: https://orcid.org/0000-0001-8237-7095)
- Marie-Annick A Clavel (ORCID: https://orcid.org/0000-0002-8924-740X)
- Jonathan Beaudoin (ORCID: https://orcid.org/0000-0002-9914-6821)
- Jorge Nuche (ORCID: https://orcid.org/0000-0002-8269-2244)
- Jérémy Bernard (ORCID: https://orcid.org/0000-0002-0645-2636)
- Benoît J. Arsenault (ORCID: https://orcid.org/0000-0003-2240-8456)
- Simon Jacob
- Antonela Zanuttini (ORCID: https://orcid.org/0009-0004-4912-4335)
- Nancy Côté (ORCID: https://orcid.org/0000-0003-4062-3643)
- Tastet Lionel
Institutions
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Université Laval (CA)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101722
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Roche